Peginterferon α-2a for the treatment of HIV infection (Q38669306)

5 September 2017

Peginterferon α-2a for the treatment of HIV infection (English)

1 reference

5 September 2017

Netanya S Utay

2

0 references

author name string

David M Asmuth

series ordinal

1

1 reference

PubMed ID

26667398

5 September 2017

Richard B Pollard

series ordinal

3

1 reference

PubMed ID

26667398

5 September 2017

language of work or name

English

0 references

publication date

15 December 2015

1 reference

Expert Opinion on Investigational Drugs

5 September 2017

1 reference

5 September 2017

25

1 reference

5 September 2017

2

1 reference

5 September 2017

249-257

1 reference

Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro.

5 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Virus interference. I. The interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Virus interference. II. Some properties of interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

The nature of the principal type 1 interferon-producing cells in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Type I interferon: understanding its role in HIV pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Differential use of the betaL subunit of the type I interferon (IFN) receptor determines signaling specificity for IFNalpha2 and IFNbeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Peginterferon alfa-2a: a review of approved and investigational uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Interferons alpha and beta as immune regulators--a new look

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Induction and regulation of IFNs during viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Inhibition of the OAS/RNase L pathway by viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

HIV-1 and interferons: who's interfering with whom?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Select host restriction factors are associated with HIV persistence during antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Interferon-inducible antiviral effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with peginterferon Alfa-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Activation and function of natural killer cell responses during viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Differential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Evidence for innate immune system activation in HIV type 1-infected elite controllers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

IFI44 suppresses HIV-1 LTR promoter activity and facilitates its latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Host and viral determinants of Mx2 antiretroviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Inhibition of HIV type 1 replication in CD4+ and CD14+ cells purified from HIV type 1-infected individuals by the 2-5A agonist immunomodulator, 2-5A(N6B).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Long-term control of HIV replication with dolutegravir and pegylated interferon alpha-2a in an HIV-infected patient with sixtuple-class resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Brief Report: Reduced Cell-Associated HTLV-2 DNA in Antiretroviral Treated HIV-1-HCV-Coinfected Patients Who Either Received Interferon-α/Ribavirin-Based Hepatitis C Therapy or Had Spontaneous HCV RNA Clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Hepatitis C therapy with interferon-α and ribavirin reduces the CD4 cell count and the total, 2LTR circular and integrated HIV-1 DNA in HIV/HCV co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

CD4+ T-Cell Deficiency in HIV Patients Responding to Antiretroviral Therapy Is Associated With Increased Expression of Interferon-Stimulated Genes in CD4+ T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

HIV-1 immunopathogenesis: how good interferon turns bad.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1132699

10.1517/13543784.2016.1132699

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference

PubMed ID

26667398